Impact of age at diagnosis on prostate cancer treatment and survival
about
Active surveillance for prostate cancer: current evidence and contemporary state of practiceProstate cancer screening in Brazil: should it be done or not?Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Impact of age on the cancer-specific survival of patients with localized renal cell carcinoma: martingale residual and competing risks analysisPredictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer.Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.Factors associated with time-to-treatment of prostate cancer in Florida.Use of treatment information from a state central cancer registry in prostate cancer research.Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.High-risk prostate cancer-classification and therapy.Treatment of localized prostate cancer in elderly patients.Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of agePhase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling studyImpact of Age, Race and Socio-economic Status on Temporal Trends in Late-Stage Prostate Cancer Diagnosis in Florida.Role of active surveillance in the management of localized prostate cancer.Temporal changes in the clinical approach to diagnosing prostate cancerPrimary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65-69 Years.Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based studyImpact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate.Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men.Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?Does prostate cancer aggressiveness change with increasing age?Risk stratification in prostate cancer screening.Risk-based prostate cancer screening: who and how?Challenging treatment decision-making in older urologic cancer patients.Locally advanced prostate cancer: optimal therapy in older patients.Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.Radical treatment of localised prostate cancer in the elderly.Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy.
P2860
Q28066534-DFFE8FD6-D691-4D49-B518-4B83787A85DEQ28068688-FC463EE1-843A-43E5-8D8C-85D71F118235Q33676037-8D3787F0-EC0E-4627-AF02-C02167DC8366Q33693397-C9326788-9DFE-4108-89A5-022FF0955A61Q33905899-4E7BF08F-093F-4E60-8B71-7D12DF371F1CQ34273541-916E1CE4-7B14-4139-8A0E-8B5CEF224050Q34465177-A7A1F8EF-4F29-4510-A71F-BD135D9C5D12Q34557264-A6FFB350-EF27-4422-A93A-4D132D6A38ECQ35102488-BD5BB798-AB13-4334-B0A6-29D54489B210Q35111947-1F72E527-2B5B-47A8-8378-0C8D7D1EE7D7Q35124541-F5432A5C-C2DA-49B2-AC36-413081D95458Q35602667-C339CBA6-F7F9-4402-994A-00543D2CA727Q35869811-7B6C0D49-6277-46C8-8DFD-673C83136793Q35912658-A5201BD8-7D1C-48A0-A1ED-F455A773748AQ36234731-F723D230-1A5E-4F07-80B5-724AFB5A5D91Q36274021-E5D59269-22B8-4863-97A6-3B0E326FE336Q36346584-E83FB230-9CC3-422F-A570-13982ADC894BQ36520452-18E7096D-C752-468D-A58D-9AF15669B5E7Q36520528-07CA2389-F97C-4ACF-9B23-871A4348E640Q36653022-F819807D-8793-4F7F-B4D2-74B6E0E453EEQ36798276-4D714132-2B45-4ABB-A0B5-F366D891B21BQ36849164-BDBB0968-55B8-4278-911D-B74A91496B13Q36859908-1AF3A227-0544-4BAB-B03E-CE5FBEFD945FQ36966828-0470CBF5-2560-4F1C-B4F6-1C823DAE82CFQ37003387-AD78AE9E-5319-416A-943F-3C6A7BD98298Q37027412-83CCCE32-E520-46DD-AC84-5DDB8CD4FBE9Q37408547-7A013A8C-D52B-4386-9CCB-C932FC61CD5CQ37538483-A9D3DA30-F730-448A-A8B5-AF1304D386D1Q37654357-EA7C26D7-F518-4896-AEEC-AB9B7BBE3997Q37864711-ECB34F1D-E7F2-45B7-A729-03BB28E60072Q38068114-0758D2E9-BA60-4D5B-A978-703275CDD78EQ38093463-C9E7D884-EA61-4042-B0EB-1C4DD57C9589Q38132679-4CB9486D-5E81-4AA4-837B-55362DE6CB35Q38149818-F568FEDB-3DAD-4C14-9538-B34F52CB2E02Q38151298-266558BE-BF32-4EDB-9C59-842FFEC601C0Q38162920-4488C8BB-0011-48B4-BC06-804B46B31604Q38195921-FC561CD1-27FB-44D4-B900-08C391303249Q38223782-5472FCFD-F453-48C5-BD19-91F69939458DQ38391501-7C300529-9080-406C-99FB-74A43F38BE10Q38399583-EAF9AFB9-D7AC-49AC-B830-CD48D19E7775
P2860
Impact of age at diagnosis on prostate cancer treatment and survival
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of age at diagnosis on prostate cancer treatment and survival
@ast
Impact of age at diagnosis on prostate cancer treatment and survival
@en
Impact of age at diagnosis on prostate cancer treatment and survival
@nl
type
label
Impact of age at diagnosis on prostate cancer treatment and survival
@ast
Impact of age at diagnosis on prostate cancer treatment and survival
@en
Impact of age at diagnosis on prostate cancer treatment and survival
@nl
prefLabel
Impact of age at diagnosis on prostate cancer treatment and survival
@ast
Impact of age at diagnosis on prostate cancer treatment and survival
@en
Impact of age at diagnosis on prostate cancer treatment and survival
@nl
P2860
P356
P1476
Impact of age at diagnosis on prostate cancer treatment and survival
@en
P2093
Peter R Carroll
Seth K Bechis
P2860
P304
P356
10.1200/JCO.2010.30.2075
P407
P577
2010-12-06T00:00:00Z